The N-MOmentum study - a randomised, placebo-controlled, double-blind trial of Inebilizumab for neuromyelitis optica spectrum disorder: randomised controlled period and open-label extension results

被引：0

作者：

Cree, B. ^{[1
]}

Bennett, J. ^{[2
]}

Kim, H. J. ^{[3
]}

Weinshenker, B. ^{[4
]}

Pittock, S. ^{[4
]}

Wingerchuk, D. ^{[5
]}

Fujihara, K. ^{[6
]}

Paul, F. ^{[7
,8
,9
]}

Cutter, G. ^{[10
]}

Marignier, R. ^{[11
]}

Green, A. ^{[1
]}

Aktas, O. ^{[12
]}

Hartung, H. -P. ^{[12
]}

Lublin, F. ^{[13
]}

Mealy, M. ^{[14
]}

Drappa, J. ^{[14
]}

Barron, G. ^{[15
]}

Madani, S. ^{[14
]}

Shi, D. ^{[14
]}

Cimbora, D. ^{[14
]}

Rees, W. ^{[14
]}

Ratchford, J. ^{[14
]}

Katz, E. ^{[14
]}

机构：

[1] Univ Calif San Francisco, Weill Inst Neurosci, Neurol, San Francisco, CA 94143 USA

[2] Univ Colorado, Sch Med, Neurol & Ophthalmol, Denver, CO USA

[3] Res Inst & Hosp Natl Canc Ctr, Goyang, South Korea

[4] Mayo Clin, Rochester, MN USA

[5] Mayo Clin, Scottsdale, AZ USA

[6] Fukushima Med Univ, Sch Med, Fukushima, Japan

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Humboldt Univ, Freie Univ Berlin, Berlin, Germany

[9] Berlin Inst Hlth, Berlin, Germany

[10] Univ Alabama Birmingham, Birmingham, AL USA

[11] Hosp Civils Lyon, Lyon, France

[12] Heinrich Heine Univ, Dusseldorf, Germany

[13] Mt Sinai Hosp, New York, NY 10029 USA

[14] Viela Bio, Gaithersburg, MD USA

[15] Astrazeneca, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

139

引用

页码：42 / 44

页数：3

共 50 条

[31] RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION OF INTRANASAL OXYTOCIN FOR AUTISM SPECTRUM DISORDER
Spanos, Marina
Bethea, Terrence
Alderman, Cheryl
Johnson, Jacqueline
Chandrasekhar, Tara
Sikich, Linmarie
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2021, 60 (10): : S162 - S162
[32] Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension
Cooper, Nichola
Bussel, James B.
Kazmierczak, Maciej
Miyakawa, Yoshitaka
Cluck, Sarah
Garcia, Rocio Lledo
Haier, Birgit
Lavrov, Andreea
Singh, Puneet
Snipes, Rose
Kuter, David J.
BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (02) : 675 - 688
[33] Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
McClung, Michael R.
O'Donoghue, Michelle L.
Papapoulos, Socrates E.
Bone, Henry
Langdahl, Bente
Saag, Kenneth G.
Reid, Ian R.
Kiel, Douglas P.
Cavallari, Ilaria
Bonaca, Marc P.
Wiviott, Stephen D.
de Villiers, Tobias
Ling, Xu
Lippuner, Kurt
Nakamura, Toshitaka
Reginster, Jean-Yves
Rodriguez-Portales, Jose Adolfo
Roux, Christian
Zanchetta, Jose
Zerbini, Cristiano A. F.
Park, Jeong-Gun
Im, KyungAh
Cange, Abby
Grip, Laura T.
Heyden, Norman
DaSilva, Carolyn
Cohn, Dosinda
Massaad, Rachid
Scott, Boyd B.
Verbruggen, Nadia
Gurner, Deborah
Miller, Deborah L.
Blair, Micki L.
Polis, Adam B.
Stoch, S. Aubrey
Santora, Arthur
Lombardi, Antonio
Leung, Albert T.
Kaufman, Keith D.
Sabatine, Marc S.
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (12): : 899 - 911
[34] A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder
Paterson, R
Douglas, C
Hallmayer, J
Hagan, M
Krupenia, Z
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1999, 33 (04): : 494 - 502
[35] FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder
Ye Chen
Zhang Xueying
Cui Jiaqu
Chen Qiyi
Qin Huanlong
Li Ning
Du Yasong
Zhao Xiaoxin
Yang Rong
Lu Jubao
Lv Xiaoqiong
Ma Chunlian
Wang Yu
Chen Shidong
Kuang Guifang
Zhao Dongmei
Fang Shuanfeng
Zhang Xujing
Yang Binrang
Wang Yanxia
Li Ling
Yuan Song
Zhou Xiang
Zhang Beihua
Jiang Lin
Ji Hong
BMJ OPEN, 2022, 12 (01):
[36] The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial
Amin, Sam
Mallick, Andrew A.
Edwards, Hannah
Cortina-Borja, Mario
Laugharne, Matthew
Likeman, Marcus
O'Callaghan, Finbar J. K.
ECLINICALMEDICINE, 2021, 32
[37] A randomised, double-blind, placebo-controlled, multi-centre trial to evaluate the safety and efficacy of eculizumab in patients with relapsing neuromyelitis optica: the PREVENT study
Wingerchuk, D. M.
Palace, J.
Cavus, I.
O'Brien, F.
Pittock, S. J.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 759 - 759
[38] ASSESSMENT OF FLUOXETINE IN STROKE RECOVERY (AFFINITY): RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED TRIAL
Hankey, G.
Hackett, M.
Almeida, O.
Flicker, L.
Mead, G.
Dennis, M.
Etherton-Beer, C.
Ford, A.
Billot, L.
Jan, S.
Anderson, C.
Gommans, J.
Lundstrom, E.
Thang-Nguyen, H.
INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 4 - 4
[39] Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation
Plazzi, Giuseppe
Ruoff, Chad
Lecendreux, Michel
Dauvilliers, Yves
Rosen, Carol L.
Black, Jed
Parvataneni, Rupa
Guinta, Diane
Wang, Youyu Grace
Mignot, Emmanuel
LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (07): : 483 - 494
[40] LongoVital® and herpes labialis:: a randomised, double-blind, placebo-controlled study
Pedersen, A
ORAL DISEASES, 2001, 7 (04) : 221 - 225

← 1 2 3 4 5 →